NASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free XBIT Stock Alerts $6.63 +0.72 (+12.18%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.59▼$7.0050-Day Range$4.20▼$6.9052-Week Range$3.05▼$7.24Volume110,857 shsAverage Volume44,660 shsMarket Capitalization$201.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get XBiotech alerts: Email Address Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About XBiotech Stock (NASDAQ:XBIT)XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Read More XBIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIT Stock News HeadlinesMarch 18, 2024 | investorplace.comXBIT Stock Earnings: XBiotech Reported Results for Q4 2023March 15, 2024 | americanbankingnews.comShort Interest in XBiotech Inc. (NASDAQ:XBIT) Grows By 35.4%March 18, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 13, 2024 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Stock Passes Above 50 Day Moving Average of $5.41March 8, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Quince Therapeutics and XBiotechFebruary 17, 2024 | finance.yahoo.comXBIT Mar 2024 5.000 callJanuary 18, 2024 | morningstar.comXBiotech Inc XBITJanuary 8, 2024 | bizjournals.comA top Austin biopharmaceutical company is doubling down on its Austin campusMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: January 4, 2024 | finance.yahoo.comXBiotech to Begin Constructing New R&D Facility on its 48-acre CampusDecember 15, 2023 | msn.comARCT, EHTH and CRTO are among after hour moversDecember 5, 2023 | finance.yahoo.comCompanies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In GrowthNovember 14, 2023 | finanznachrichten.deXBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid ArthritisNovember 14, 2023 | finance.yahoo.comDr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisSeptember 26, 2023 | finance.yahoo.comXBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeAugust 8, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialAugust 8, 2023 | finance.yahoo.comXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialJune 30, 2023 | thestreet.comXBiotech Cancer Drug Survival Claim Falls Apart Under ScrutinyMay 23, 2023 | finanznachrichten.deXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 22, 2023 | finance.yahoo.comFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 17, 2023 | finance.yahoo.comXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesApril 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 17, 2023 | finance.yahoo.comXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 9, 2023 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insidersFebruary 15, 2023 | finance.yahoo.comThe past three years for XBiotech (NASDAQ:XBIT) investors has not been profitableNovember 11, 2022 | finance.yahoo.comXBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)See More Headlines Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Next Earnings (Estimated)6/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIT CUSIPN/A CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,900,000.00 Net MarginsN/A Pretax Margin-7,401.66% Return on Equity-9.96% Return on Assets-9.71% Debt Debt-to-Equity RatioN/A Current Ratio38.61 Quick Ratio38.61 Sales & Book Value Annual Sales$4.01 million Price / Sales45.62 Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book0.76Miscellaneous Outstanding Shares30,440,000Free Float21,793,000Market Cap$182.94 million OptionableOptionable Beta1.44 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John Simard (Age 62)Founder, President, CEO & Chairman Comp: $4.67MDr. Sushma Shivaswamy Ph.D. (Age 46)Chief Scientific Officer Comp: $381.24kMs. Angela Hu (Age 40)Director of Finance, Principal Financial & Accounting Officer and Financial Controller Key CompetitorsVaccitechNASDAQ:VACCscPharmaceuticalsNASDAQ:SCPHCorMedixNASDAQ:CRMDOvid TherapeuticsNASDAQ:OVIDAlimera SciencesNASDAQ:ALIMView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 9,068 shares on 3/11/2024Ownership: 2.896%Vanguard Group Inc.Bought 9,068 shares on 2/15/2024Ownership: 2.896%Bridgeway Capital Management LLCBought 5,352 shares on 2/15/2024Ownership: 0.475%Citadel Advisors LLCSold 5,200 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 26,279 shares on 2/13/2024Ownership: 0.260%View All Institutional Transactions XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed in 2024? XBiotech's stock was trading at $4.00 at the start of the year. Since then, XBIT shares have increased by 65.8% and is now trading at $6.63. View the best growth stocks for 2024 here. Are investors shorting XBiotech? XBiotech saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 537,500 shares, an increase of 35.4% from the February 14th total of 397,000 shares. Based on an average trading volume of 36,700 shares, the days-to-cover ratio is presently 14.6 days. Approximately 2.7% of the company's shares are short sold. View XBiotech's Short Interest. When is XBiotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024. View our XBIT earnings forecast. What is John Simard's approval rating as XBiotech's CEO? 20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ). When did XBiotech IPO? (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO. Who are XBiotech's major shareholders? XBiotech's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.90%), Vanguard Group Inc. (2.90%), Bridgeway Capital Management LLC (0.48%), Northern Trust Corp (0.26%), National Bank of Canada FI (0.08%) and Citadel Advisors LLC (0.00%). View institutional ownership trends. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIT) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.